Table 2.
Comparison of Characteristics of Survivors and Non-survivors With Idiosyncratic DILI.
| Variable | Survivors (N = 1084) | Non-survivors (N = 153) | P value |
|---|---|---|---|
| Age (Years) | 42 ± 16. | 48 ± 17 | 0.001 |
| Duration of treatment (days) IQR |
26 (10–60) | 24 (12–101) | 0.80 |
| Weight (kg) | 55 ± 14 | 56 ± 14 | 0.50 |
| BMI | 22.0 ± 4 | 22 ± 5 | 0.60 |
| ATD | 85.4% | 14.6% | 0.027 |
| Serum total protein (g/dl) | 6.6 ± 2.5 | 6.0 ± 1.1 | 0.005 |
| Serum albumin (g/dl) | 3.1 ± 0.7 | 2.7 ± 0.8 | 0.001 |
| Total bilirubin (mg/dl) | 7.3 ± 8.6 | 14.2 ± 15.4 | 0.001 |
| Direct bilirubin (mg/dl) | 5.1 ± 6.4 | 8.6 ± 6 | 0.001 |
| AST (IU/L) IQR |
211 (117–700) | 286 (152–758) | 0.004 |
| ALT (IU/L) IQR |
236 (109–480) | 315 (128–731) | 0.04 |
| ALP(IU/L) IQR |
176 (123–276) | 190 (130–315) | 0.40 |
| GGT (IU/L) IQR |
132 (64–296) | 101 (56.207) | 0.40 |
| Serum creatinine (mg/dl) | 0.9 ± 0.8 | 1.4 ± 1 | 0.001 |
| INR | 1.5 ± 1.2 | 2.9 ± 2.5 | 0.001 |
| HB (g/dl) | 11.3 ± 2.1 | 10.8 ± 2 | 0.015 |
| WBC (10/dl) IQR |
8500 (6200–11100) | 9320 (7000–13480) | 0.50 |
| Neutrophils (%) | 68 ± 15 | 73 ± 13 | 0.005 |
| Platelets (105/dl) | 2.4 ± 1.1 | 2.1 ± 1.3 | 0.008 |
| MELD | 16.8 ± 7.5 | 28.3 ± 10.4 | 0.001 |
| Females | 47.6% | 55.6% | 0.064 |
| Admission | 65.7% | 88.3% | 0.001 |
| Jaundice | 63.9% | 88.8% | 0.001 |
| Skin rashes | 20.3% | 15.3% | 0.15 |
| Encephalopathy | 4.1% | 52.7% | 0.001 |
| Ascites | 12.5% | 42.7% | 0.001 |
| Alcohol | 10% | 17% | 0.16 |
| Diabetes | 6% | 8.5% | 0.28 |
| Severe disease | 23% | 93.5% | 0.001 |
Abbreviations: ATD: anti-tuberculosis drugs, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, BMI: Body Mass Index, GGT: gamma glutamyl transferase, INR: International normalized ratio, IQR: inter quartile range, MELD: Model for end stage liver disease, WBC: white blood cells.